Compound Management comes of age By Ian Yates The changing role of compound management in recent years has seen an often under-valued and under-resourced function being recognised as a key part of the drug discovery process. This article examines the challenges faced by compound management teams and, at a high… Read More
Secondary Screening Workstations - The emergence of compact turnkey solutions that work By Dr John Comley With the launch of new workstations focused on secondary screening applications not only are we witnessing the shrinkage of laboratory automation but we are seeing the emergence of true walk-away solutions, ie set up… Read More
New Visions in Ophthalmic Drug Development By Dr Benjamin R. Yerxa, Dr Ward M. Peterson and Robin S.Whitsell Over the last 10 years we have seen the introduction of several new 'ophthalmology only' pharmaceutical products emerge such as Trusopt (dorzolamide, Merck) and Xalatan (latanoprost, Pharmacia). Innovative products such as these… Read More
Better drugs by MICROARRAY By Dr Mark Schena Microarray analysis allows the elucidation of biological processes and pathways on a genomic scale. This revolutionary technology promises an unprecedented view of drug action and side reaction, the ability to identify drug targets and optimise lead compounds, the capacity to predict patient… Read More
Finding and minding R&D talent the hidden human cost of merger mania By Sue Harris This article examines the impact on R&D staff of the current economic uncertainty, the raft of mega-mergers and the growth of the biotech sector. Senior management repeatedly comment that finding, motivating and retaining talented individuals… Read More
Predictive chemoinformatics applications to the pharmaceutical industry By Dr Leslie J. Browne and Laurie L.Taylor While significant advances in chemoinformatics present tremendous opportunities to improve human health, the future of chemoinformatics in the pharmaceutical industry is not without significant challenges. Chemoinformatics is the result of collective advances in chemistry, biology,… Read More
Protein Biochips - On the threshold of success By Dr Steven Bodovitz and Felicia Gentile With sales of protein biochips set to top $700 million in 2006, we present a current overview of this fast moving technology and the applications for the pharmaceutical industry as a whole. On the surface… Read More
CNS Drug Discovery - Realising the dream By Dr Julie C. Barnes and Dr Ann G. Hayes Over the years, the discovery of drugs for treating neurological and psychiatric diseases has proven to be one of the highest risk areas in the pharmaceutical industry. Despite the huge resources that have… Read More
By Dr Ian Gilham The increasing cost of healthcare along with new opportunities for improved treatments puts ever increasing pressures on healthcare budgets. In recent years the diagnostic industry in particular has been the target of a number of cost-cutting exercises by governments and payers aimed at restricting the utilisation… Read More
The importance of using human-based models in gene and drug discovery By Dr Michael G. Palfreyman, Dr Vinod Charles and Jeffrey Blander Completion of the human genome sequence has opened an unprecedented opportunity to discover the genetic contribution to many of the complex diseases that afflict humans and to use… Read More
By Dr Roger A. Edwards, Dr Kai Zhang and Louise Firth Different companies have employed various techniques and strategies for addressing productivity issues in the chemistry functions within pharmaceutical discovery and preclinical development. We benchmarked lead optimisation, clinical candidate selection, and chemistry support for preclinical development before IND filing in… Read More
Drug development for skin diseases based on functional genomics By Dr Jorn-Peter Halle With the high number of sufferers from skin disease around the world, it is astonishing that there are relatively few treatments available and that many of these only serve to relieve symptoms. Can drug development based on… Read More
Nanolitre Dispensing - On the point of delivery By Dr John Comley Precise low-volume liquid handling methodologies are still sought after by those interested in enabling miniaturised HTS. This article reviews the need for nanolitre dispensing and provides a current perspective on those emerging technologies that have the potential to… Read More
SNP Genotyping in Drug Development By Dr Nicholas C. Dracopoli and Dr Kim E. Zerba SNP-based candidate gene analyses are likely to have a significant impact on predicting drug efficacy and will, undoubtedly, impact on the pharmaceutical industry's development strategies as a whole over the next few years. The human… Read More
High throughput genomics and drug discovery - parallel universes or a continuum? By Dr Mark Beggs and Audrey Long HTS has been in place for approximately 10-12 years and has achieved a threeorder of magnitude scale up. Genomics has been in a 'high throughput' mode for approximately four years for… Read More
Chemical microarrays - The drug discovery superhighway By Elaine Seeskin While producing targets was once the bottleneck in the drug discovery process, in the post-genomic era this has been superseded by the requirement for high-quality lead structures. As a result of the pool of genomic data and countless unvalidated targets… Read More